Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD)

NCT04337827 is registered in ClinicalTrials.gov with Deepa Jagadeesh as lead sponsor.

NCT NCT04337827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04337827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD)
Lead sponsor
Deepa Jagadeesh
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2020
Completion date
December 19, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-transplant lymphoproliferative disorder